$VOR

RA CAPITAL MANAGEMENT, L.P. sold $4K of VOR (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 213 indirectly-held shares of Vor Biopharma Inc. (VOR) at $19.75 on 2026-07-16.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jul 21, 2026, 8:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VOR
Neutral
medium confidence
Mentioned
$VOR
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VORNeutralLow
01

Why it matters

The only new fact is the reported open-market sale details (date, shares, price, and post-transaction holdings). There is no accompanying narrative about business performance, trials, or guidance.

02

Market read

Traders may note insider selling, but the disclosed transaction is small and lacks any fundamental catalyst in the text.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the transaction value is very small, reducing signal-to-noise versus larger or repeated sales.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-21, covering a sale dated 2026-07-16.

Background

The article is an SEC Form 4 insider transaction disclosure for Vor Biopharma, reported by RA Capital Management, L.P. as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$VORNeutralMedium confidence
Context

RA Capital Management, a 10% owner, filed a Form 4 showing an open-market sale of 213 VOR shares at $19.75 on 2026-07-16.

Expected impact

Limited near-term impact; any reaction is likely noise unless follow-on sales or larger transactions appear.

Evidence & confidence

The filing is primary-source (Form 4) but the transaction size ($4,206.75) is small, and there is no accompanying company-specific catalyst or guidance change in the text.

Market effects

None indicated; this is a single-company ownership transaction with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

The sale could be non-informational (taxes, diversification, or routine liquidity) and does not indicate a change in company outlook.

Key entities

  • Vor Biopharma Inc.

    Subject of the Form 4 insider transaction disclosure.

  • RA Capital Management, L.P.

    Reported the open-market sale of shares in indirect holdings.

Related articles